{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:19:13Z","timestamp":1790972353206,"version":"4.1.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2002,6,1]]},"DOI":"10.1038\/sj.leu.2402531","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T14:33:06Z","timestamp":1031149986000},"page":"1015-1027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"T","family":"Robak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kasznicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,6,5]]},"reference":[{"key":"BF2402531_CR1","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","volume":"333","author":"C Rozman","year":"1995","unstructured":"Rozman C, Montserrat E . Chronic lymphocytic leukemia treatment N Engl J Med 1995 333: 1052\u20131057","journal-title":"N Engl J Med"},{"key":"BF2402531_CR2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/0959-8049(95)00368-1","volume":"31A","author":"D Catovsky","year":"1995","unstructured":"Catovsky D, Murphy RL . Key issues in the treatment of chronic lymphocytic leukemia (CLL) Eur J Cancer 1995 31A: 2146\u20132154","journal-title":"Eur J Cancer"},{"key":"BF2402531_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V85.2.307.307","volume":"85","author":"S O'Brien","year":"1995","unstructured":"O'Brien S, del Giglio A, Keating M . Advances in the biology and treatment of B-cell chronic lymphocytic leukemia Blood 1995 85: 307\u2013318","journal-title":"Blood"},{"key":"BF2402531_CR4","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJM200012143432410","volume":"343","author":"G Dighiero","year":"2000","unstructured":"Dighiero G, Binet JL . When and how to treat chronic lymphocytic leukemia N Engl J Med 2000 343: 1799\u20131801","journal-title":"N Engl J Med"},{"key":"BF2402531_CR5","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/1097-0142(19851115)56:10<2369::AID-CNCR2820561004>3.0.CO;2-N","volume":"56","author":"E Montserrat","year":"1985","unstructured":"Montserrat E, Alcala A, Parody R, Domingo A, Garcia-Conde J, Bueno J, Ferran C, Sanz MA, Giralt M, Rubio D . Treatment of chronic lymphocytic leukemia in advanced stage: a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine and prednisone Cancer 1985 56: 2369\u20132375","journal-title":"Cancer"},{"key":"BF2402531_CR6","doi-asserted-by":"crossref","unstructured":"French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia Blood 1990 75: 1422\u20131425","DOI":"10.1182\/blood.V75.7.1422.1422"},{"key":"BF2402531_CR7","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2107::AID-CNCR7>3.0.CO;2-L","volume":"79","author":"B Jaksic","year":"1997","unstructured":"Jaksic B, Brugiatelli M, Krc I, Losonczi H, Hoowiecki J, Planinc-Peraica A, Kusec R, Morabito F, Iacopino P, Lutz D . High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna Cancer 1997 79: 2107\u20132114","journal-title":"Cancer"},{"key":"BF2402531_CR8","first-page":"2723","volume":"96","author":"T Robak","year":"2000","unstructured":"Robak T, B\u0142o\u00f1ski JZ, Kasznicki M, BBasi\u00f1ska\u0142asiBasi\u00f1skantilde;ska-Morawiec M, Krykowski E, Dmoszy\u00f1ska A, MrugaMrugaa-piewak\u0142a-piewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasi\u00f1ski I, Zdziarska B, Kotlarek-Haus S . Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial Blood 2000 96: 2723\u20132729","journal-title":"Blood"},{"key":"BF2402531_CR9","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 2000 343: 1750\u20131757","journal-title":"N Engl J Med"},{"key":"BF2402531_CR10","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","volume":"338","author":"G Dighiero","year":"1998","unstructured":"Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P . Chlorambucil in indolent chronic lymphocytic leukemia N Engl J Med 1998 338: 1506\u20131514","journal-title":"N Engl J Med"},{"key":"BF2402531_CR11","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V86.7.2463.2463","volume":"86","author":"MS Tallman","year":"1995","unstructured":"Tallman MS, Hakimian D . Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders Blood 1995 86: 2463\u20132474","journal-title":"Blood"},{"key":"BF2402531_CR12","first-page":"1005","volume":"53","author":"JC Adkins","year":"1997","unstructured":"Adkins JC, Peters DH, Markham A . Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies Drugs 1997 53: 1005\u20131037","journal-title":"Drugs"},{"key":"BF2402531_CR13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","volume":"92","author":"MJ Keating","year":"1998","unstructured":"Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H . Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 1998 92: 1165\u20131171","journal-title":"Blood"},{"key":"BF2402531_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2000.01850.x","volume":"108","author":"T Robak","year":"2000","unstructured":"Robak T, B\u0142o\u00f1ski JZ, Kasznicki M, Konopka L, Ceglarek B, Dmoszy\u00f1ska A, Soroka-Wojtaszko M, Skotnicki AB, Nowak W, Dwilewicz-Trojaczek J, Tomaszewska A, Hellmann A, Lewandowski K, Kuliczkowski K, Potoczek S, Zdziarska B, Hansz J, Kroll R, Komarnicki M, Ho\u0142owiecki J, Grieb P . Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia \u2013 updated results of the multicenter study of 378 patients Br J Haematol 2000 108: 357\u2013368","journal-title":"Br J Haematol"},{"key":"BF2402531_CR15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-0609.1995.tb00244.x","volume":"55","author":"M Brugiatelli","year":"1995","unstructured":"Brugiatelli M, Jaksic B, Planinc-Peraica A, Kusec R, Ostojic S, Callea V, Iacopino P, Morabito F, Stelitano C, Lutz D . Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial Eur J Haematol 1995 55: 158\u2013163","journal-title":"Eur J Haematol"},{"key":"BF2402531_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hon.2900060103","volume":"6","author":"C Shustik","year":"1988","unstructured":"Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L . Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation Hematol Oncol 1988 6: 7\u201312","journal-title":"Hematol Oncol"},{"key":"BF2402531_CR17","doi-asserted-by":"crossref","unstructured":"French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (Stage A): results of a randomized clinical trial on 612 patients Blood 1990 75: 1414\u20131421","DOI":"10.1182\/blood.V75.7.1414.bloodjournal7571414"},{"key":"BF2402531_CR18","doi-asserted-by":"crossref","unstructured":"CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials J Natl Cancer Inst 1999 91: 861\u2013868","DOI":"10.1093\/jnci\/91.10.861"},{"key":"BF2402531_CR19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.2830290307","volume":"29","author":"BD Cheson","year":"1988","unstructured":"Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA . Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendation of the National Cancer Institute sponsored working group Am J Hematol 1988 29: 152\u2013163","journal-title":"Am J Hematol"},{"key":"BF2402531_CR20","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR . National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia. Revised guidelines for diagnosis and treatment Blood 1996 87: 4990\u20134997","journal-title":"Blood"},{"key":"BF2402531_CR21","doi-asserted-by":"crossref","unstructured":"French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients Br J Haematol 1990 76: 45\u201357","DOI":"10.1111\/j.1365-2141.1990.tb07835.x"},{"key":"BF2402531_CR22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V78.4.895.895","volume":"78","author":"S Molica","year":"1991","unstructured":"Molica S . Progression and survival studies in early chronic lymphocytic leukemia Blood 1991 78: 895\u2013899","journal-title":"Blood"},{"key":"BF2402531_CR23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1749-6632.1958.tb42649.x","volume":"68","author":"LG Israels","year":"1958","unstructured":"Israels LG, Galton DAG, Till M, Wiltshaw E . Clinical evaluation of CB 1348 in malignant lymphoma and related diseases Ann NY Acad Sci 1958 68: 915\u2013925","journal-title":"Ann NY Acad Sci"},{"key":"BF2402531_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10428199609054821","volume":"23","author":"A Begleiter","year":"1996","unstructured":"Begleiter A, Mowat M, Israels LG, Johnston JB . Chlorambucil in chronic lymphocytic leukemia: mechanism of action Leuk Lymphoma 1996 23: 187\u2013201","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR25","first-page":"S103","volume":"8 (Suppl.\u20091)","author":"A Begleiter","year":"1994","unstructured":"Begleiter A, Lee K, Israels LG, Mowat MR, Johnston JB . Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy Leukemia 1994 8 (Suppl.\u20091): S103\u2013S106","journal-title":"Leukemia"},{"key":"BF2402531_CR26","first-page":"89","volume":"5 (Suppl.)","author":"E Montserrat","year":"1991","unstructured":"Montserrat E, Fontanilles M, Estape J . Treatment of chronic lymphocytic leukemia: A preliminary report of Spanish (PETHEMA) trials Leuk Lymphoma 1991 5 (Suppl.): 89\u201391","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.V50.6.1049.1049","volume":"50","author":"A Sawitsky","year":"1977","unstructured":"Sawitsky A, Rai KR, Glidewell O, Silver RT . Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia Blood 1977 50: 1049\u20131059","journal-title":"Blood"},{"key":"BF2402531_CR28","first-page":"437","volume":"30","author":"B Jaksic","year":"1988","unstructured":"Jaksic B, Brugiatelli M . High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL IGCI CLL\u201301 trial Nouv Rev Fr Hematol 1988 30: 437\u2013442","journal-title":"Nouv Rev Fr Hematol"},{"key":"BF2402531_CR29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000204115","volume":"93","author":"AG Bosanquet","year":"1995","unstructured":"Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D . Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for and effectiveness of treatment suggested by DiSC assay Acta Haematol 1995 93: 73\u201379","journal-title":"Acta Haematol"},{"key":"BF2402531_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/10428199109103389","volume":"5 (Suppl.)","author":"D Catovsky","year":"1991","unstructured":"Catovsky D, Richards S, Fooks J, Hamblin TJ . CLL trials in United Kingdom: The Medical Research Council CLL Trials 1, 2 and 3 Leuk Lymphoma 1991 5 (Suppl.): 105\u2013111","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/1097-0142(197303)31:3<502::AID-CNCR2820310303>3.0.CO;2-7","volume":"31","author":"T Han","year":"1973","unstructured":"Han T, Ezdinli EZ, Shimaoka K, Desai DV . Chlorambucil vs combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia Cancer 1973 31: 502\u2013508","journal-title":"Cancer"},{"key":"BF2402531_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0305-7372(96)90013-4","volume":"22","author":"IW Flinn","year":"1996","unstructured":"Flinn IW, Grever MR . Chronic lymphocytic leukaemia Cancer Treat Rev 1996 22: 1\u201313","journal-title":"Cancer Treat Rev"},{"key":"BF2402531_CR33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0268-960X(93)90003-M","volume":"7","author":"E Monsterrat","year":"1993","unstructured":"Monsterrat E, Rozman C . Chronic lymphocytic leukaemia treatment Blood Rev 1993 7: 164\u2013175","journal-title":"Blood Rev"},{"key":"BF2402531_CR34","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/1097-0142(19851115)56:10<2369::AID-CNCR2820561004>3.0.CO;2-N","volume":"56","author":"E Montserrat","year":"1985","unstructured":"Montserrat E, Alcala A, Parody R, Domingo A, Garcia-Conde J, Bueno J, Ferran C, Sanz MA, Giralt M, Rubio D, Auton J, Estape J, Rozman C . Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine and prednisone Cancer 1985 56: 2369\u20132375","journal-title":"Cancer"},{"key":"BF2402531_CR35","doi-asserted-by":"crossref","unstructured":"French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia Blood 1990 75: 1422\u20131425","DOI":"10.1182\/blood.V75.7.1422.1422"},{"key":"BF2402531_CR36","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.1991.9.5.770","volume":"9","author":"B Raphael","year":"1991","unstructured":"Raphael B, Andersen JW ., Silber R, Oken M, Moore D, Bennett J, Bonner H, Hahn R, Knospe WH, Mazza J, Glick J. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinial trial J Clin Oncol 1991 9: 770\u2013776","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/10428199109103386","volume":"5 (Suppl.)","author":"E Kimby","year":"1991","unstructured":"Kimby E, Melstedt H . Chlorambucil\/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type: a randomized trial Leuk Lymphoma 1991 5 (Suppl.): 93\u201396","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR38","first-page":"433","volume":"30","author":"MM Hansen","year":"1998","unstructured":"Hansen MM, Andersen E . Birgeus H, Christensen BE, Christensen TG, Gisler C. CHOP versus prednisone + chlorambucil in chronic lymphocytic leukemia: preliminary results of a randomized multicenter study Nouv Rev Fr Hematol 1998 30: 433\u2013436","journal-title":"Nouv Rev Fr Hematol"},{"key":"BF2402531_CR39","doi-asserted-by":"crossref","unstructured":"French Cooperative Group on Chronic Lymphocytic Leukemia. Long term results of CHOP regimen in stage C chronic lymphocytic leukemia Br J Haematol 1989 73: 334\u2013340","DOI":"10.1111\/j.1365-2141.1989.tb07749.x"},{"key":"BF2402531_CR40","first-page":"1110","volume":"60","author":"S Kempin","year":"1982","unstructured":"Kempin S, Lee BJ III, Thaler HT, Koziner B, Hecht S, Gee T, Arlin Z, Little C, Straus D, Reich L, Philips E, Al-Mondhiry H, Dowling M, Mayer K, Clarkson B . Combination chemotherapy of advanced chronic lymphocytic leukemia: The M-2 protocol (vincristin, BCNU, cyclophosphamide, melphalan and prednisone) Blood 1982 60: 1110\u20131121","journal-title":"Blood"},{"key":"BF2402531_CR41","first-page":"429","volume":"30","author":"E Montserrat","year":"1988","unstructured":"Montserrat E, Alcala A, Alonso C, Besalduch J, Moraleda JM, Garcia-Conde J, Gutierrez M, Gomis F, Garijo J, Guzman MC, Estapa J, Rozman C . A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan and prednisone in the treatment of chronic lymphocytic leukemia stages B and C Nouv Rev Fr Hematol 1988 30: 429\u2013432","journal-title":"Nouv Rev Fr Hematol"},{"key":"BF2402531_CR42","first-page":"157","volume":"2","author":"MJ Keating","year":"1988","unstructured":"Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ . Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia Leukemia 1988 2: 157\u2013164","journal-title":"Leukemia"},{"key":"BF2402531_CR43","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","volume":"82","author":"S O'Brien","year":"1993","unstructured":"O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M . Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment Blood 1993 82: 1695\u20131700","journal-title":"Blood"},{"key":"BF2402531_CR44","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V72.3.1069.bloodjournal7231069","volume":"72","author":"LD Piro","year":"1988","unstructured":"Piro LD, Carrera CJ, Beutler E, Carson DA . 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia Blood 1988 72: 1069\u20131073","journal-title":"Blood"},{"key":"BF2402531_CR45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1989.7.4.433","volume":"7","author":"RO Dillman","year":"1989","unstructured":"Dillman RO, Mick R, McIntyre OR . Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B J Clin Oncol 1989 7: 433\u2013438","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","volume":"340","author":"E Beutler","year":"1992","unstructured":"Beutler E . Cladribine (2-chlorodeoxyadenosine) Lancet 1992 340: 952\u2013956","journal-title":"Lancet"},{"key":"BF2402531_CR47","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","volume":"96","author":"D Genini","year":"2000","unstructured":"Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, Leoni LM . Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria Blood 2000 96: 3537\u20133543","journal-title":"Blood"},{"key":"BF2402531_CR48","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1999.17.5.1574","volume":"17","author":"JM Foran","year":"1999","unstructured":"Foran JM, Oscier D, Orchard J, Johnson SA, Tighe M, Cullen MH, de Takats PG, Kraus C, Klein M, Lister TA . Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with \u2018low-grade\u2019 non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia J Clin Oncol 1999 17: 1574\u20131579","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR49","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1992.10.10.1514","volume":"10","author":"J Liliemark","year":"1992","unstructured":"Liliemark J, Albertioni F, Hassan M, Juliusson G . On the bioavailability of oral and subcutaneous 2-chloro-2-deoxyadenosine in humans: alternative routes of administration J Clin Oncol 1992 10: 1514\u20131518","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.thj.6200113","volume":"2","author":"D Oscier","year":"2001","unstructured":"Oscier D, Orchard JA, Culligan D, Cunningham D, Johnson S, Parker A, Klein M, Gieschen H . The bioavailability of oral fludarabine phosphate is unaffected by food Hematology J 2001 2: 316\u2013321","journal-title":"Hematology J"},{"key":"BF2402531_CR51","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2001.19.22.4252","volume":"19","author":"MA Boogartes","year":"2001","unstructured":"Boogartes MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL, Binet JL, Feremans W, Marcus R, Bosch F, Klein VM . Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia J Clin Oncol 2001 19: 4252\u20134258","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR52","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1996.14.7.2160","volume":"14","author":"G Juliusson","year":"1996","unstructured":"Juliusson G, Christiansen I, Hansen MM, Johnson S, Kimby E, Elmhorn-Rosenborg A, Liliemark J . Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia J Clin Oncol 1996 14: 2160\u20132166","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR53","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","volume":"347","author":"S Johnson","year":"1996","unstructured":"French Cooperative Group on CLL Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W . Multicentre prospective randomised trial of fludarabine versus cyclophosphamide doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia Lancet 1996 347: 1432\u20131438","journal-title":"Lancet"},{"key":"BF2402531_CR54","first-page":"1130","volume":"9","author":"A Delannoy","year":"1995","unstructured":"Delannoy A, Martiat P, Gala JL, Deneys V, Ferrant A, Bosly A, Schieff JM, Michaux JL . 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL) Leukemia 1995 9: 1130\u20131135","journal-title":"Leukemia"},{"key":"BF2402531_CR55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","volume":"13","author":"A Saven","year":"1995","unstructured":"Saven A, Lemon RH, Kosty M, Beutler E, Piro LD . 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia J Clin Oncol 1995 13: 570\u2013574","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/sj.leu.2401368","volume":"13","author":"T Robak","year":"1999","unstructured":"Robak T, B\u0142o\u00f1ski JZ, Urba\u00f1ska-Ry H, Basi\u00f1ka-Morawiec M, Skotnicki AB . 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger Leukemia 1999 13: 518\u2013523","journal-title":"Leukemia"},{"key":"BF2402531_CR57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00000421-199910000-00018","volume":"22","author":"A Tefferi","year":"1999","unstructured":"Tefferi A, Levitt R, Li CY, Schroeder G, Tschetter LK, Michalak JC, Krook JE, Witzig TE . Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia Am J Clin Oncol 1999 22: 509\u2013516","journal-title":"Am J Clin Oncol"},{"key":"BF2402531_CR58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.V96.1.71","volume":"96","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR . Fludarabine and cyclophosphamide with filgastrim support in patients with previously untreated indolent lymphoid malignancies Blood 2000 96: 71\u201375","journal-title":"Blood"},{"key":"BF2402531_CR59","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.leu.2401892","volume":"14","author":"MA Weiss","year":"2000","unstructured":"Weiss MA, Glenn M, Maslak P, Rahman Z, Noy A, Zelenetz A, Scheinberg DA, Golde DW . Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 2000 14: 1577\u20131582","journal-title":"Leukemia"},{"key":"BF2402531_CR60","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","volume":"98","author":"M Leporrier","year":"2001","unstructured":"Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugler P, Desablens B, Rapp M-J, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet J-L, Chastang C . Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients Blood 2001 98: 2319\u20132325","journal-title":"Blood"},{"key":"BF2402531_CR61","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1996.14.7.2160","volume":"14","author":"G Juliusson","year":"1996","unstructured":"Juliusson G, Christiansen I, Hansen MM, Johnson S, Kimby E, Elmhorn-Rosenborg A, Liliemark J . Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia J Clin Oncol 1996 14: 2160\u20132166","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR62","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428190109060345","volume":"41","author":"T Robak","year":"2001","unstructured":"Robak T, B\u0142o\u00f1ski JZ, Kasznicki M . Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia? Leuk Lymphoma 2001 41: 545\u2013557","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR63","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","volume":"19","author":"VA Morrison","year":"2001","unstructured":"Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA . Impact of therapy with chlorambucil, fludarabine or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011 J Clin Oncol 2001 19: 3611\u20133621","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR64","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","volume":"129","author":"EJ Anaissie","year":"1998","unstructured":"Anaissie EJ, Kontoyiannis DP, O'Brian S, Kantarjian H, Robertson L, Lerner S, Keating MJ . Infections in patients with chronic lymphocytic leukemia treated with fludarabine Ann Intern Med 1998 129: 559\u2013566","journal-title":"Ann Intern Med"},{"key":"BF2402531_CR65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/10428199309054731","volume":"11","author":"F Di Raimondo","year":"1993","unstructured":"Di Raimondo F, Guistolisi R, Cacciola E, Kantarjian H, Robertson LB, Keating MJ . Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine Leuk Lymphoma 1993 11: 63\u201368","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2141.1995.tb05300.x","volume":"91","author":"H Myint","year":"1995","unstructured":"Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, Hamon MD, Oscier DG, Hamblin TJ . Fludarabine related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia Br J Haematol 1995 91: 341\u2013344","journal-title":"Br J Haematol"},{"key":"BF2402531_CR67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0609.1997.tb00933.x","volume":"58","author":"T Robak","year":"1997","unstructured":"Robak T, B\u0142asi\u00f1ska-Morawiec M, Krykowski E, Hellmann A, Konopka L . Autoimmune haemolytic anaemia in patients with chronic lymphocytic anemia treated with 2-chlorodeoxyadenosine (cladribine) Eur J Haematol 1997 58: 109\u2013113","journal-title":"Eur J Haematol"},{"key":"BF2402531_CR68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/10428199809068575","volume":"29","author":"RC Chasty","year":"1998","unstructured":"Chasty RC, Myint H, Oscier DG, Orchard JA, Bussutil DP, Hamon MD, Prentice AG . Copplestone JA. Autoimmunehaemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA) Leuk Lymphoma 1998 29: 391\u2013398","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ajh.2830480423","volume":"48","author":"RA Fleischman","year":"1995","unstructured":"Fleischman RA, Croy D . Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia Am J Hematol 1995 48: 293","journal-title":"Am J Hematol"},{"key":"BF2402531_CR70","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792","volume":"95","author":"FR Mauro","year":"2000","unstructured":"Mauro FR, Foa R, Carretti R, Giannarelli D . Coluzzi S, Maudelli F, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic and prognostic features Blood 2000 95: 2786\u20132792","journal-title":"Blood"},{"key":"BF2402531_CR71","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3109\/10428190109097653","volume":"40","author":"E Van Den Neste","year":"2001","unstructured":"Van Den Neste E, Delannoy A, Feemans W, Ferrant A, Michaux JL . Second primary tumors and immune phenomena after fludarabine or 2-chloro-2-deoxyadenosine treatment Leuk Lymphoma 2001 40: 541\u2013550","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.leu.2400523","volume":"11","author":"SH Kroft","year":"1997","unstructured":"Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC . Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA) Leukemia 1997 11: 170","journal-title":"Leukemia"},{"key":"BF2402531_CR73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1365-2141.1998.00612.x","volume":"100","author":"JA Orchard","year":"1998","unstructured":"Orchard JA, Bolam S, Oscier DG . Association of myelodysplastic changes with purine analogues Br J Haematol 1998 100: 677\u2013679","journal-title":"Br J Haematol"},{"key":"BF2402531_CR74","first-page":"268","volume":"105","author":"E Van Den Neste","year":"1999","unstructured":"Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Michaux L, Hagemeijer A, Scheiff JM, Bosly A, Straetmans N, Ferrant A . Myelodysplastic syndrome with monosomy 5 and\/or 7 following therapy with 2-chloro-2\u2032-deoxyadenosine Br J Haematol 1999 105: 268\u2013270","journal-title":"Br J Haematol"},{"key":"BF2402531_CR75","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.1999.17.8.2454","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Vena DA, Barrett J, Frreidlin B . Second malignancies as a consequence of nucleoside analog therapy for chronic lymphocytic leukemias J Clin Oncol 1999 17: 2454\u20132460","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR76","first-page":"1268","volume":"85","author":"C Marotta","year":"2000","unstructured":"Marotta C, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F . Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy Hematologica 2000 85: 1268\u20131270","journal-title":"Hematologica"},{"key":"BF2402531_CR77","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/sj.leu.2401431","volume":"13","author":"E Van Den Neste","year":"1999","unstructured":"Van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM, Gillis E, Leveugle P, Deneys V, Ferrant A, Van den Berghe G . Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2\u2032-deoxyadenosine Leukemia 1999 13: 918\u2013925","journal-title":"Leukemia"},{"key":"BF2402531_CR78","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","volume":"19","author":"S O'Brien","year":"2001","unstructured":"O'Brien S, Kantarjian H, Cortes J, Beran M, Koller C, Giles F, Lerner S, Keating M . Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 2001 19: 1414\u20131420","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR79","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-2141.2001.02959.x","volume":"114","author":"M Hallek","year":"2001","unstructured":"Hallek M, Schmitt B, Wilheim M, Busch R, Krober A, Fostisch H, Sezer O, Herold M, Knauf W, Wendtner C . Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukemia (CLL): results of a phase II study of the German CLL Study Group Br J Haematol 2001 114: 342\u2013348","journal-title":"Br J Haematol"},{"key":"BF2402531_CR80","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.leu.2401783","volume":"14","author":"E Van Den Neste","year":"2000","unstructured":"Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Michaux L, Sonet A, Bosly A, Doyen C, Mineur P, Andre M, Straetmans N, Coche E, Venet C, Duprez T, Ferrant A . Phase I\/II study of 2-chloro-2\u2032-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma Leukemia 2000 14: 1136\u20131142","journal-title":"Leukemia"},{"key":"BF2402531_CR81","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bjc.6690195","volume":"79","author":"FM Laurencet","year":"1999","unstructured":"Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P . Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies Br J Cancer 1999 79: 1215\u20131219","journal-title":"Br J Cancer"},{"key":"BF2402531_CR82","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1046\/j.1365-2141.1999.01212.x","volume":"104","author":"R Frewin","year":"1999","unstructured":"Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S . Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders Br J Haematol 1999 104: 612\u2013613","journal-title":"Br J Haematol"},{"key":"BF2402531_CR83","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.2000.18.5.987","volume":"18","author":"HS Hochster","year":"2000","unstructured":"Hochster HS, Oken MM, Winter JN, Gordon LI, Raphael BG, Bennett JM, Cassileth PA . Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up \u2013 a report from the Eastern Cooperative Oncology Group J Clin Oncol 2000 18: 987\u2013994","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR84","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1046\/j.1365-2141.1999.01765.x","volume":"107","author":"M Lazzarino","year":"1999","unstructured":"Lazzarino M, Orlandi E, Baldanti F, Furione M, Pagnucco G, Astori C, Arcaini L, Viglio A, Paulli M, Gerna G, Bernasconi C . The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders Br J Haematol 1999 107: 877\u2013882","journal-title":"Br J Haematol"},{"key":"BF2402531_CR85","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/sj.leu.2402172","volume":"15","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Li CY, Reeder CB, Geyer SM, Allmer C, Levitt R, Michalak JC, Addo F, Krook JE, Witzig TE, Scheafer PL, Milliard JA . A phase II study of sequential prednisone and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia Leukemia 2001 15: 1171\u20131175","journal-title":"Leukemia"},{"key":"BF2402531_CR86","first-page":"1959","volume":"10","author":"A Begleiter","year":"1996","unstructured":"Begleiter A, Wang H, Verburg L, Lee K, Israels LG, Mowat MR, Johnston JB . In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia Leukemia 1996 10: 1959\u20131965","journal-title":"Leukemia"},{"key":"BF2402531_CR87","first-page":"140","volume":"8 (Suppl.\u20091)","author":"JB Johnston","year":"1994","unstructured":"Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A . Combination therapy with nucleoside analogs and alkylating agents Leukemia 1994 8 (Suppl.\u20091): 140\u2013143","journal-title":"Leukemia"},{"key":"BF2402531_CR88","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JCO.1994.12.3.569","volume":"12","author":"A Tefferi","year":"1994","unstructured":"Tefferi A, Witzig TE, Reid JM, Li CY, Ames MM . Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma J Clin Oncol 1994 12: 569\u2013574","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR89","first-page":"1290","volume":"8","author":"M Weiss","year":"1994","unstructured":"Weiss M, Spiess T, Berman E, Kempin S . Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia Leukemia 1994 8: 1290\u20131293","journal-title":"Leukemia"},{"key":"BF2402531_CR90","first-page":"361","volume":"7","author":"L Elias","year":"1993","unstructured":"Elias L, Stack-Novack D, Head DR, Grever MR, Veick JK, Chapman RA, Godwin JE, Metz EN, Appalbaun FR . A phase I trial of combination fludarabine monphosphate and chlorambucil in chronic leymphocytic leukemia: A South West Oncology Group Study Leukemia 1993 7: 361\u2013365","journal-title":"Leukemia"},{"key":"BF2402531_CR91","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","volume":"94","author":"B Bellosillo","year":"1999","unstructured":"Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J . In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in B-cell chronic lymphocytic leukemia Blood 1999 94: 2836\u20132843","journal-title":"Blood"},{"key":"BF2402531_CR92","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/10428190009148404","volume":"36","author":"KU Chow","year":"2000","unstructured":"Chow KU, Rummel MJ, Weidmann E, Ries J, Jantschke P, Boehrer S, Pourebrahim F, Napieralski S, Stein J, Martin H, Hoelzer D, Mitrou PS . Induction of apoptosis by 2-chloro-2\u2032-deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone Leuk Lymphoma 2000 36: 559\u2013567","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR93","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/1099-1069(200012)18:4<141::AID-HON666>3.0.CO;2-#","volume":"18","author":"SA Johnson","year":"2000","unstructured":"Johnson SA, Thomas W . Therapeutic potential of purine analogue combination in the treatment of lymphoid malignancies Hematol Oncol 2000 18: 141\u2013153","journal-title":"Hematol Oncol"},{"key":"BF2402531_CR94","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","volume":"14","author":"P McLaughlin","year":"1996","unstructured":"McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F . Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma J Clin Oncol 1996 14: 1262\u20131268","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR95","first-page":"943","volume":"9","author":"LE Robertson","year":"1995","unstructured":"Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ . Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia Leukemia 1995 9: 943\u2013945","journal-title":"Leukemia"},{"key":"BF2402531_CR96","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008312432416","volume":"10","author":"MJ Rummel","year":"1999","unstructured":"Rummel MJ, Kafer G, Pfreundschuh M, Jager E, Reinhardt U, Mitrou PS, Hoelzer D, Bergmann L . Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia. a German multicenter phase II study Ann Oncol 1999 10: 183\u2013188","journal-title":"Ann Oncol"},{"key":"BF2402531_CR97","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0609.2001.00303.x","volume":"66","author":"T Robak","year":"2001","unstructured":"Robak T, G\u00f3ra-Tybor J, Lech-Mara\u00f1da E, B\u0142o\u00f1ski JZ, Kasznicki M . Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies Eur J Haematol 2001 66: 188\u2013194","journal-title":"Eur J Haematol"},{"key":"BF2402531_CR98","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.leu.2402216","volume":"15","author":"T Robak","year":"2001","unstructured":"Robak T, B\u0142o\u00f1ski JZ, Kasznicki M, G\u00f3ra-Tybor J, Dwilewicz-Trojaczek J, Boguradzki P, Konopka L, Ceglarek B, Su\u0142ek J, Kuliczkowski K, Woowiec D, Stella-Hoowiecka B, Skotnicki AB, Nowak W, Moskwa-Soroka B, Dmoszy\u00f1ska A, Cabecka M . Cladribine combined with mitoxantrone and cyclophosphamide as first line therapy in chronic lymphocytic leukemia Leukemia 2001 15: 1510\u20131516","journal-title":"Leukemia"},{"key":"BF2402531_CR99","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood.V74.5.1747.1747","volume":"74","author":"HG Drexler","year":"1989","unstructured":"Drexler HG, Gignac SM, Jones RA, Scott CS, Pettit GR, Hoffbrand AV . Bryostain 1 induces differentation of B-chronic lymphocytic leukemia cells Blood 1989 74: 1747\u20131757","journal-title":"Blood"},{"key":"BF2402531_CR100","first-page":"445","volume":"4","author":"RM Mohammad","year":"1998","unstructured":"Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM . Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies Clin Cancer Res 1998 4: 445\u2013453","journal-title":"Clin Cancer Res"},{"key":"BF2402531_CR101","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199909093735","volume":"33","author":"M Hoffman","year":"1999","unstructured":"Hoffman M, Xu JC, Lesser M, Rai K . Cytotoxicity of 2-chlorodeoxyadenosine (cladribine, 2-CdA) in combination with other chemotherapy drugs against two lymphoma cell lines Leuk Lymphoma 1999 33: 141\u2013145","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR102","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10428199909145949","volume":"36","author":"FJ Giles","year":"1999","unstructured":"Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ . Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study Leuk Lymphoma 1999 36: 57\u201365","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR103","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.annonc.a010604","volume":"7","author":"G Juliusson","year":"1996","unstructured":"Juliusson G, Liliemark J . Long term survival following cladribine (2-chlorodeoxyadenosine therapy in previously treated patients with chronic lymphocytic leukemia Ann Oncol 1996 7: 373\u2013379","journal-title":"Ann Oncol"},{"key":"BF2402531_CR104","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10428199109103394","volume":"5 (Suppl.)","author":"A Saven","year":"1991","unstructured":"Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD . 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia Leuk Lymphoma 1991 5 (Suppl.): 133\u2013138","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428190009057630","volume":"37","author":"MJ Keating","year":"2000","unstructured":"Keating MJ, Smith TL, Lerner S, O'Brien S, Robertson LE, Kantarjian H, Freireich EJ . Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia Leuk Lymphoma 2000 37: 71\u201385","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR106","first-page":"224","volume":"81","author":"F Morabito","year":"1996","unstructured":"Morabito F, Stelitano C, Callea I, Filangeri M, Oliva B, Sculli G, Callea V, Nobile F, Briugiatelli M . In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlroambucil: correlation with clinico-hematological and immunophenotypic features Haematologica 1996 81: 224\u2013231","journal-title":"Haematologica"},{"key":"BF2402531_CR107","first-page":"1875","volume":"9","author":"A Begleiter","year":"1995","unstructured":"Begleiter A, Verburg L, Ashique A, Lee K, Israels LG, Mowat MR, Johnston JB . Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-\u03b2-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro Leukemia 1995 9: 1875\u20131881","journal-title":"Leukemia"},{"key":"BF2402531_CR108","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199210083271504","volume":"327","author":"G Juliusson","year":"1992","unstructured":"Juliusson G, Elmhorn-Rosenborg A, Liliemark J . Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine N Engl J Med 1992 327: 1056\u20131061","journal-title":"N Engl J Med"},{"key":"BF2402531_CR109","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM199402033300504","volume":"330","author":"S O'Brien","year":"1994","unstructured":"O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M . Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy N Engl J Med 1994 330: 319\u2013322","journal-title":"N Engl J Med"},{"key":"BF2402531_CR110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10428199609054812","volume":"23","author":"M Itala","year":"1996","unstructured":"Itala M, Remes K . The COP regimen is not a feasible treatment for advanced refractory chronic lymphocytic leukemia Leuk Lymphoma 1996 23: 137\u2013141","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10428199409051654","volume":"13","author":"G Juliusson","year":"1994","unstructured":"Juliusson G, Liliemark J . Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance Leuk Lymphoma 1994 13: 75\u201380","journal-title":"Leuk Lymphoma"},{"key":"BF2402531_CR112","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O'Brien","year":"2001","unstructured":"O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ . Rituximab dose-escalation trial in chronic lymphocytic leukemia J Clin Oncol 2001 19: 2165\u20132170","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR113","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez J, Rosenberg J, Kunkel L, Flinn IW . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity J Clin Oncol 2001 19: 2153\u20132164","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR114","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","volume":"98","author":"D Huhn","year":"2001","unstructured":"Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B . Rituximab therapy of patients with B-cell chronic lymphocytic leukemia Blood 2001 98: 1326\u20131331","journal-title":"Blood"},{"key":"BF2402531_CR115","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H . Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia J Clin Oncol 1997 15: 1567\u20131574","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR116","first-page":"52","volume":"26","author":"MJS Dyer","year":"1999","unstructured":"Dyer MJS . The role of CAMPATH-I antibodies in the treatment of lymphoid malignancies Semin Oncol 1999 26: 52\u201357","journal-title":"Semin Oncol"},{"key":"BF2402531_CR117","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","volume":"93","author":"A \u00d6sterborg","year":"1996","unstructured":"\u00d6sterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ . Humanised CD52 monoclonal antibody Campath-IH as first-line treatment in chronic lymphocytic leukemia Br J Haematol 1996 93: 151\u2013153","journal-title":"Br J Haematol"},{"key":"BF2402531_CR118","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","volume":"96","author":"AL Bowen","year":"1997","unstructured":"Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D . Subcutaneous CAMPATH-1H in fludarabine-resistant\/ relapsed chronic lymphocytic and B-prolymphocytic leukaemia Br J Haematol 1997 96: 617\u2013619","journal-title":"Br J Haematol"},{"key":"BF2402531_CR119","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","volume":"15","author":"R Pawson","year":"1997","unstructured":"Pawson R, Dyer MJ, Barge R, Motutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D . Treatment of T-cell prolymphocytic leukemia with human CD52 antibody J Clin Oncol 1997 15: 2667\u20132672","journal-title":"J Clin Oncol"},{"key":"BF2402531_CR120","first-page":"587","volume":"27","author":"JC Byrd","year":"2000","unstructured":"Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR . Novel therapies for chronic lymphocytic leukemia in the 21st century Semin Oncol 2000 27: 587\u2013597","journal-title":"Semin Oncol"},{"key":"BF2402531_CR121","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.leu.2401201","volume":"12","author":"L Sutton","year":"1998","unstructured":"Sutton L, Maloun K, Gonzales H, Zouabl H, Aza N, Bocaccio C, Charlotte F, Cosset JM, Gubarre J, Leblond V, Merle-Berial H, Binet JL . Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia Leukemia 1998 12: 1699\u20131707","journal-title":"Leukemia"},{"key":"BF2402531_CR122","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/sj.leu.2402178","volume":"15","author":"K Van Besien","year":"2001","unstructured":"Van Besien K, Keralavarma B, Devine S, Stock W . Allogenic and autologous transplantation for chronic lymphocytic leukemia Leukemia 2001 15: 1317\u20131325","journal-title":"Leukemia"},{"key":"BF2402531_CR123","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","volume":"88","author":"D Provan","year":"1996","unstructured":"Provan D, Bartett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG . Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation Blood 1996 88: 2228\u20132235","journal-title":"Blood"},{"key":"BF2402531_CR124","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","volume":"98","author":"AC Rawstron","year":"2001","unstructured":"Rawstron AC, Kennedy B, Evans PAS, Davies FE, Richards SJ, Haynes AP, Russel NH, Hale G, Morgan GJ, Jack AS, Hillman P . Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy Blood 2001 98: 29\u201335","journal-title":"Blood"},{"key":"BF2402531_CR125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2402036","volume":"15","author":"J Esteve","year":"2001","unstructured":"Esteve J, Villamor N, Colomer D, Cervantes F, Campo E, Carreras E, Montserrat E . Stem cell transplantation for chronic lymphocytic leukemia: different outcame after autologous and allogenic transplantation and correlation with minimal residual disease status Leukemia 2001 15: 445\u2013451","journal-title":"Leukemia"},{"key":"BF2402531_CR126","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.V97.7.1929","volume":"97","author":"A Noy","year":"2001","unstructured":"Noy A, Verma R, Glenn M, Masiak P, Rahman ZU, Keenan JR, Weiss M, Filippa D, Zelenetz AD . Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol Blood 2001 97: 1929\u20131936","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402531","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:59:55Z","timestamp":1648749595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6,1]]}},"alternative-id":["BF2402531"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402531","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,1]]},"assertion":[{"value":"12 April 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}